The purpose of this investigation is to demonstrate whether triptolide can inhibit TNF-α selectively and to study the mechanism. The ability of triptolide to inhibit the production of TNF-α and IFN-γ stimulated by ...The purpose of this investigation is to demonstrate whether triptolide can inhibit TNF-α selectively and to study the mechanism. The ability of triptolide to inhibit the production of TNF-α and IFN-γ stimulated by lipopolysaccharide (LPS) and phytohemagglutinin (PHA) on peripheral blood mononuclear cell (PBMC) from healthy donors was measured by ELISA assays. The immunological mechanism of action of triptolide on TNF-α was investigated by pre-treatment with triptolide of PBMC and monocytes followed by analysis with Flow Cytometry (FCM). The inhibition of TNF-α and IFN-γ by triptolide occurred in a dose dependent manner and the IC 50 was equal to 5-10 ng/ml for TNF-α and 0.1-1 ng/ml for IFN-γ. The concentrations of TNF-α measured after the different pre-treatments with triptolide on PBMC and monocytes are consistent with its effects on a population of CD14 +/TNF-α + monocytes shown on FCM. The two methods of pre-treatments with triptolide may suggest different clinical significances. Immunophenotyping analysis with FCM revealed that triptolide may compete with LPS for binding to the CD14 receptor. The study provides basic evidence that triptolide may be used as an anti-inflammatory reagent for treatment of leprosy reactions.展开更多
文摘The purpose of this investigation is to demonstrate whether triptolide can inhibit TNF-α selectively and to study the mechanism. The ability of triptolide to inhibit the production of TNF-α and IFN-γ stimulated by lipopolysaccharide (LPS) and phytohemagglutinin (PHA) on peripheral blood mononuclear cell (PBMC) from healthy donors was measured by ELISA assays. The immunological mechanism of action of triptolide on TNF-α was investigated by pre-treatment with triptolide of PBMC and monocytes followed by analysis with Flow Cytometry (FCM). The inhibition of TNF-α and IFN-γ by triptolide occurred in a dose dependent manner and the IC 50 was equal to 5-10 ng/ml for TNF-α and 0.1-1 ng/ml for IFN-γ. The concentrations of TNF-α measured after the different pre-treatments with triptolide on PBMC and monocytes are consistent with its effects on a population of CD14 +/TNF-α + monocytes shown on FCM. The two methods of pre-treatments with triptolide may suggest different clinical significances. Immunophenotyping analysis with FCM revealed that triptolide may compete with LPS for binding to the CD14 receptor. The study provides basic evidence that triptolide may be used as an anti-inflammatory reagent for treatment of leprosy reactions.
